PTC THERAPEUTICS INC
NASDAQ: PTCT (PTC Therapeutics, Inc.)
Last update: 2 hours ago89.55
0.98 (1.11%)
| Previous Close | 88.57 |
| Open | 89.01 |
| Volume | 1,219,143 |
| Avg. Volume (3M) | 1,799,175 |
| Market Cap | 7,428,113,408 |
| Price / Earnings (Forward) | 56.82 |
| Price / Sales | 8.28 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Profit Margin | 33.56% |
| Operating Margin (TTM) | 82.43% |
| Diluted EPS (TTM) | 6.39 |
| Quarterly Revenue Growth (YOY) | 459.70% |
| Current Ratio (MRQ) | 3.89 |
| Operating Cash Flow (TTM) | 691.65 M |
| Levered Free Cash Flow (TTM) | 526.00 M |
| Return on Assets (TTM) | 24.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | PTC Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -2.25 |
|
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.40% |
| % Held by Institutions | 101.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Janus Henderson Group Ltd. | 31 Mar 2026 | 7,193,433 |
| Armistice Capital, Llc | 31 Mar 2026 | 2,074,449 |
| Hood River Capital Management Llc | 31 Mar 2026 | 1,664,559 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GRAVIER PIERRE | - | 78.06 | -3,494 | -272,742 |
| Aggregate Net Quantity | -3,494 | |||
| Aggregate Net Value ($) | -272,742 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 78.06 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GRAVIER PIERRE | Officer | 14 Jul 2026 | Sell (-) | 3,494 | 78.06 | 272,742 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |